News

Cookie Notification

We use cookies to collect information about how our website is used and to improve the visitor experience. You can change your browser's cookie settings at any time. Please review our privacy policy for more information. OK

Media Contact

Stephen Schultz
VP Investor Relations (U.S.)
T: 917-280-2424 / 401 500 6570
sschultz@gwpharm.com
 

Recent Press Releases

Dec 13, 2007
GW Pharmaceuticals plc (AIM: GWP) welcomes the publication today by the UK regulator, the Medicines and Healthcare products Regulatory Agency (MHRA) of a Public Information Report on Sativex, GW’s cannabinoid spray
Dec 03, 2007
GW Pharmaceuticals plc (AIM: GWP) today announces that it has started a new Phase III trial of Sativex® in Multiple Sclerosis (MS) Spasticity.
Nov 26, 2007
GW Pharmaceuticals plc (AIM: GWP) and Otsuka Pharmaceutical Co., Ltd.
Nov 12, 2007
GW Pharmaceuticals plc (AIM: GWP) today announces that The International Association of the Study of Pain has published online the results of a study in its official journal Pain, showing that Sativex® successfully
Oct 22, 2007
GW Pharmaceuticals plc (AIM: GWP) and Bayer HealthCare Pharmaceuticals announce that Health Canada, the Canadian regulatory agency, has issued a Qualifying Notice for the approval of Sativex® in the relief of cancer
Oct 22, 2007
GW Pharmaceuticals plc (GWP:AIM) announces positive results from a placebo-controlled “randomized withdrawal” study of Sativex® in patients with neuropathic pain due to Multiple Sclerosis (MS).
Oct 17, 2007
GW Pharmaceuticals plc (AIM: GWP) today announces that the Journal of Clinical Therapeutics has published the results of a study which show that Sativex® provides effective long term treatment of central neuropathic
Aug 30, 2007
GW Pharmaceuticals plc (AIM: GWP) announces that patient recruitment is now complete in its pivotal Phase III trial in people with multiple sclerosis (MS) suffering from central neuropathic pain.
Aug 07, 2007
GW Pharmaceuticals plc (AIM: GWP) and Bayer Inc., a subsidiary of Bayer AG, today announce that Health Canada has approved Sativex®, a cannabis derived pharmaceutical treatment, as adjunctive analgesic treatment in
Jul 09, 2007
GW Pharmaceuticals plc and Otsuka Pharmaceutical Co., Ltd today announce a major long term strategic cannabis alliance.

Pages